An observational study in Pyelonephritis and Prognostic, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Acute obstructive pyelonephritis is a condition with a high risk of complications and may require admission to the intensive care unit.
Most of the available data on this condition comes from small, retrospective, single-centre series.
To date, no large-scale study has examined the factors associated with the prognosis of patients admitted to intensive care for acute obstructive pyelonephritis.
The aim of this study is to describe the population and prognosis of patients admitted to the intensive care unit for the management of acute obstructive pyelonephritis, and to identify factors associated with a poor prognosis in these patients.
The retrospective and multicenter study consists of a retrospective and pseudonymous collection of data from medical reports of patients treated, over the period 2015-2022, in each intensive care unit agreeing to participate, .
Investigators from each participating center will be responsible for screening on all hospitalized patients over the period 2015-2022. Patients who have been hospitalized for the management of acute obstructive pyelonephritis will be included, in the absence of non-inclusion criteria.
79 studies on the registry are indexed under Pyelonephritis; 12 are open to participants now.
This study's enrollment of 575 is above the median of 153 across 15 observational studies indexed under Pyelonephritis.
Browse Pyelonephritis studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients meeting the eligibility criteria over the period 2015-2022 will be included in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The primary endpoint will be a combined endpoint of death, and/or stage 3 AKI ( KDIGO classification), and/or non-recovery of renal function.
Time frame: up to 30 days after admission to intensive care
Death
Time frame: up to 30 days after admission to intensive care
Stage 3 Acute kidney injury (KDIGO classification)
Time frame: up to 30 days after admission to intensive care
failure to recover renal function
defined as creatinine levels greater than 150% of baseline value
Time frame: up to 30 days after admission to intensive care .
the incidence of acute renal failure defined by KDIGO 1
Time frame: up to 30 days after admission to intensive care
the incidence of acute renal failure defined by KDIGO 2 and 3
Time frame: up to 30 days after admission to intensive care
the incidence of Renal replacement therapy
Time frame: up to 30 days after admission to intensive care
the incidence of non-recovery of renal fuction
Time frame: up to 30 days after admission to intensive care
The number of days alive without Renal replacement therapy
Time frame: up to 30 days after admission to intensive care
The number of days alive without catecholamines
Time frame: up to 30 days after admission to intensive care
The number of days alive without antibiotics
Time frame: up to 30 days after admission to intensive care
The number of days alive without
Time frame: up to 30 days after admission to intensive care
Death rate
Time frame: up to 30 days after admission to intensive care
Ran from May 2024 to primary completion in Nov 2025, 18 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →